Immune gene therapy of cancer

AKBULUT H.

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.50, ss.1679-1690, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 50
  • Basım Tarihi: 2020
  • Doi Numarası: 10.3906/sag-2005-327
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1679-1690
  • Anahtar Kelimeler: Immunotherapy, gene therapy, cancer, cytosine deaminase, granulocyte-macrophage colony-stimulating factor, TUMOR-INFILTRATING LYMPHOCYTES, CARCINOEMBRYONIC ANTIGEN CEA, COLONY-STIMULATING FACTOR, PROTEIN BOOST VACCINE, ADOPTIVE CELL THERAPY, CAR T-CELLS, ADENOVIRAL VECTORS, GM-CSF, PHASE-I, DENDRITIC CELLS
  • Ankara Üniversitesi Adresli: Evet

Özet

Cancer gene therapy emerged as a promising treatment modality 3 decades ago. However, the failure of the first gene therapy trials in cancer treatment has decreased its popularity. Likewise, immunotherapy has followed a similar course. While it was a popular and promising treatment with IL-2 and interferon and cancer vaccines in the 1980s, it later lost its popularity. Immunotherapy became one of the main options for cancer treatment with the successful use of immune checkpoint inhibitors in clinics approximately 10 years ago. The success of immunotherapy has increased even more with the introduction of cancer gene therapy methods in this area. With the identification of the oncolytic herpes simplex virus and Chimeric antigen receptor (CAR) T-cells, immune gene therapy has become an essential modality in cancer treatments such as surgery, radiotherapy, chemotherapy, and targeted therapies.